| Literature DB >> 29457103 |
Mitsuhiko Oohata1, Yuko Aoki1, Michiko Miyata1, Hiroki Mizobe1, Kenji S Suzuki1.
Abstract
BACKGROUND: There has been an increase in the number of Japanese patients with lumbar spinal canal stenosis (LSCS) who complain of chronic pain or motor disturbance in the lower back or extremities. These patients are often treated with anti-convulsive drugs, opioids, antidepressants, acetaminophen, or nonsteroidal anti-inflammatory drugs, all of which can cause side effects. For this reason, Japanese traditional herbal medicine (Kampo) is of interest, because it produces fewer adverse reactions. The aim of this retrospective cohort study was to analyze the effects of Kampo in patients with LSCS.Entities:
Keywords: Japanese traditional herbal medicine; Kampo; Lumbar spinal canal stenosis; Oriental medicine; Pain management
Year: 2017 PMID: 29457103 PMCID: PMC5804655 DOI: 10.1186/s40981-017-0130-5
Source DB: PubMed Journal: JA Clin Rep ISSN: 2363-9024
Demographic profile and source of referral of the patients
| Item | Group K ( | Group N ( |
|
|---|---|---|---|
| Age (years) | 73.3 ± 9.4 | 70.8 ± 9.5 | 0.16 |
| Male/female | 60/51 | 21/19 | 0.87 |
| Height (cm) | 158.4 ± 10.4 | 158.3 ± 8.8 | 0.95 |
| Weight (kg) | 58.0 ± 11.7 | 62.3 ± 11.6 | 0.06 |
| Source | |||
| Our hospital | |||
| Orthopedics (%) | 68 | 58 | |
| Neurosurgery (%) | 3 | 12 | |
| Neurology (%) | 3 | 2 | |
| Others (%) | 1 | 0 | |
| Another institution | |||
| Pain clinic (%) | 5 | 10 | |
| Others (%) | 10 | 8 | |
| No introduction (%) | 9 | 8 | |
Values are mean ± SD or number of patients
Details of prescribed Kampo medicines
| Name of drugs | Number of patients |
|---|---|
| Gosha-jinki-gan | 51 |
| Hachimi-jiō-gan | 50 |
| Shakuyaku-kanzo-tō | 31 |
| Keishi-ka-jyutsubu-tō | 26 |
| Bushi-matsu | 24 |
| Sokei-kakketsu-tō | 15 |
| Tokishigyaku-ka-goshui-shokyo-tō | 12 |
| Yokukan-san | 10 |
| Gorei-san | 10 |
| Others | 65 |
The number of patients who were prescribed each drug and were followed-up
| Pregabalin | Opioid | Antidepressant | NSAIDs/acetaminophen | ||
|---|---|---|---|---|---|
Group K ( | Prescription | 69/111 (62.2%) | 74/111 (66.7%) | 22/111 (19.8%) | 54/111 (48.6%) |
| Decrease | 45/69*** (65.2%) | 52/74*** (70.3%) | 17/22** (77.3%) | 7/54 (13.0%) | |
| Discont | 36/69*** (52.2%) | 41/74*** (55.4%) | 16/22* (72.7%) | 6/54 (11.1%) | |
Group N ( | Prescription | 19/40 (47.5%) | 28/40 (70.0%) | 6/40 (15.0%) | 20/40 (50.0%) |
| Decrease | 2/19 (10.5%) | 9/28 (32.1%) | 2/6 (33.3%) | 2/20 (10.0%) | |
| Discont | 2/19 (10.5%) | 4/28 (14.3%) | 2/6 (33.3%) | 2/20 (10.0%) |
Decrease decrease in the dose of drug prescribed, Discont discontinuation of the drug prescribed
*p < 0.1; **p < 0.05; ***p < 0.01 vs. group N
Duration of hospital visits and outcomes
| Patients | Group K ( | Group N ( |
|
|---|---|---|---|
Ended treatment Visiting period (months) | 49.5% 12.0 (4.5, 24.5) | 35.0% 5.0 (3.3, 16.3) | 0.113 0.172 |
Continued treatment Visiting period (months) | 42.3% 35.0 (20.5, 54.0) | 27.5% 41.0 (19.0, 69.5) | 0.098 0.592 |
Dropped out Visiting period (months) | 8.1%* 8.0 (4.0, 26.0) | 37.5% 34.0 (16.5, 50.5) | < 0.0001 0.172 |
Values are percentages of patients (%) and median (interquartile range)
*p < 0.05 vs. group N